PURPOSE: Romidepsin is a potent histone deacetylase inhibitor under clinical development. The objective of this study was to evaluate the effect of demographic, clinical, and pharmacogenetic covariates on the pharmacokinetics of romidepsin in patients with T-cell lymphoma. EXPERIMENTAL DESIGN: Pharmacokinetic assessment was done in 98 patients enrolled in a phase II study who received 14 or 18 mg/m2 of romidepsin as a 4-hour infusion on day 1 during their first treatment cycle. Population modeling was done using a nonlinear mixed effects modeling approach to explore the effects of polymorphic variations in CYP3A4, CYP3A5, SLCO1B3, and ABCB1, all of which encode genes thought to be involved in romidepsin disposition. RESULTS: A two-compartment model with linear kinetics adequately described the romidepsin disposition. Population clearance was 15.9 L/h with between-patient variability of 37%. ABCB1 2677G>T/A variant alleles tended toward a reduced clearance and lower volume of tissue distribution, but this was not supported by a statistical significance. Genetic variations in CYP3A4/5 and SCLO1B3 had no effect on the systemic exposure. CONCLUSION: The population pharmacokinetic analysis indicates moderate interindividual variability in romidepsin pharmacokinetics and no clinically relevant covariates associated with the unexplained pharmacokinetic variability of romidepsin in this population.
PURPOSE:Romidepsin is a potent histone deacetylase inhibitor under clinical development. The objective of this study was to evaluate the effect of demographic, clinical, and pharmacogenetic covariates on the pharmacokinetics of romidepsin in patients with T-cell lymphoma. EXPERIMENTAL DESIGN: Pharmacokinetic assessment was done in 98 patients enrolled in a phase II study who received 14 or 18 mg/m2 of romidepsin as a 4-hour infusion on day 1 during their first treatment cycle. Population modeling was done using a nonlinear mixed effects modeling approach to explore the effects of polymorphic variations in CYP3A4, CYP3A5, SLCO1B3, and ABCB1, all of which encode genes thought to be involved in romidepsin disposition. RESULTS: A two-compartment model with linear kinetics adequately described the romidepsin disposition. Population clearance was 15.9 L/h with between-patient variability of 37%. ABCB1 2677G>T/A variant alleles tended toward a reduced clearance and lower volume of tissue distribution, but this was not supported by a statistical significance. Genetic variations in CYP3A4/5 and SCLO1B3 had no effect on the systemic exposure. CONCLUSION: The population pharmacokinetic analysis indicates moderate interindividual variability in romidepsin pharmacokinetics and no clinically relevant covariates associated with the unexplained pharmacokinetic variability of romidepsin in this population.
Authors: Maryam Fouladi; Wayne L Furman; Thomas Chin; Burgess B Freeman; Lorina Dudkin; Clinton F Stewart; Mark D Krailo; Roseanne Speights; Ashish M Ingle; Peter J Houghton; John Wright; Peter C Adamson; Susan M Blaney Journal: J Clin Oncol Date: 2006-08-01 Impact factor: 44.544
Authors: Tristan M Sissung; Klaus Mross; Seth M Steinberg; Dirk Behringer; William D Figg; Alex Sparreboom; Stephan Mielke Journal: Eur J Cancer Date: 2006-09-06 Impact factor: 9.162
Authors: R L Piekarz; R Robey; V Sandor; S Bakke; W H Wilson; L Dahmoush; D M Kingma; M L Turner; R Altemus; S E Bates Journal: Blood Date: 2001-11-01 Impact factor: 22.113
Authors: Victor Sandor; Susan Bakke; Robert W Robey; Min H Kang; Mikhail V Blagosklonny; Jonathon Bender; Rebecca Brooks; Richard L Piekarz; Eben Tucker; William D Figg; Kenneth K Chan; Barry Goldspiel; Antonio Tito Fojo; Stanley P Balcerzak; Susan E Bates Journal: Clin Cancer Res Date: 2002-03 Impact factor: 12.531
Authors: John L Marshall; Naiyer Rizvi; John Kauh; William Dahut; Manuela Figuera; Min H Kang; William D Figg; Irving Wainer; Christoff Chaissang; Megan Zhaoyang Li; Michael J Hawkins Journal: J Exp Ther Oncol Date: 2002 Nov-Dec
Authors: S D Baker; J Verweij; G A Cusatis; R H van Schaik; S Marsh; S J Orwick; R M Franke; S Hu; E G Schuetz; V Lamba; W A Messersmith; A C Wolff; M A Carducci; A Sparreboom Journal: Clin Pharmacol Ther Date: 2008-05-28 Impact factor: 6.875
Authors: Akinobu Hamada; Tristan Sissung; Douglas K Price; Romano Danesi; Cindy H Chau; Nima Sharifi; David Venzon; Kenji Maeda; Keisuke Nagao; Alex Sparreboom; Hiroaki Mitsuya; William L Dahut; William D Figg Journal: Clin Cancer Res Date: 2008-06-01 Impact factor: 12.531
Authors: Gregory Q Del Prete; Kelli Oswald; Abigail Lara; Rebecca Shoemaker; Jeremy Smedley; Rhonda Macallister; Vicky Coalter; Adam Wiles; Rodney Wiles; Yuan Li; Randy Fast; Rebecca Kiser; Bing Lu; Jim Zheng; W Gregory Alvord; Charles M Trubey; Michael Piatak; Claire Deleage; Brandon F Keele; Jacob D Estes; Joseph Hesselgesser; Romas Geleziunas; Jeffrey D Lifson Journal: Antimicrob Agents Chemother Date: 2015-12-28 Impact factor: 5.191
Authors: Ruben Niesvizky; Scott Ely; Tomer Mark; Sangeeta Aggarwal; Janice L Gabrilove; John J Wright; Selina Chen-Kiang; Joseph A Sparano Journal: Cancer Date: 2010-09-22 Impact factor: 6.860
Authors: Richard L Piekarz; Robin Frye; H Miles Prince; Mark H Kirschbaum; Jasmine Zain; Steven L Allen; Elaine S Jaffe; Alexander Ling; Maria Turner; Cody J Peer; William D Figg; Seth M Steinberg; Sonali Smith; David Joske; Ian Lewis; Laura Hutchins; Michael Craig; A Tito Fojo; John J Wright; Susan E Bates Journal: Blood Date: 2011-02-25 Impact factor: 22.113
Authors: Fabio M Iwamoto; Kathleen R Lamborn; John G Kuhn; Patrick Y Wen; W K Alfred Yung; Mark R Gilbert; Susan M Chang; Frank S Lieberman; Michael D Prados; Howard A Fine Journal: Neuro Oncol Date: 2011-03-03 Impact factor: 12.300
Authors: Tristan M Sissung; Erin R Gardner; Richard L Piekarz; Reuben Howden; Xiaohong Chen; Sukyung Woo; Ryan Franke; James A Clark; Laura Miller-DeGraff; Seth M Steinberg; David Venzon; David Liewehr; Steven R Kleeberger; Susan E Bates; Douglas K Price; Douglas R Rosing; Christopher Cabell; Alex Sparreboom; William D Figg Journal: Clin Cancer Res Date: 2010-11-24 Impact factor: 12.531
Authors: Richard L Piekarz; Robin Frye; Maria Turner; John J Wright; Steven L Allen; Mark H Kirschbaum; Jasmine Zain; H Miles Prince; John P Leonard; Larisa J Geskin; Craig Reeder; David Joske; William D Figg; Erin R Gardner; Seth M Steinberg; Elaine S Jaffe; Maryalice Stetler-Stevenson; Stephen Lade; A Tito Fojo; Susan E Bates Journal: J Clin Oncol Date: 2009-10-13 Impact factor: 44.544